121.15
Axsome Therapeutics Inc stock is traded at $121.15, with a volume of 558.37K.
It is down -0.46% in the last 24 hours and up +2.31% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$121.71
Open:
$122.04
24h Volume:
558.37K
Relative Volume:
1.00
Market Cap:
$6.05B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-18.55
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+1.01%
1M Performance:
+2.31%
6M Performance:
+23.55%
1Y Performance:
+38.36%
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AXSM
Axsome Therapeutics Inc
|
121.15 | 6.07B | 338.46M | -310.96M | -132.82M | -6.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-01-25 | Initiated | B. Riley Securities | Buy |
Sep-03-25 | Resumed | Wells Fargo | Overweight |
Jul-03-25 | Resumed | Morgan Stanley | Overweight |
Jun-03-25 | Initiated | Oppenheimer | Outperform |
Apr-07-25 | Initiated | Jefferies | Buy |
Feb-11-25 | Initiated | Deutsche Bank | Buy |
Dec-31-24 | Reiterated | Mizuho | Outperform |
Sep-03-24 | Initiated | Wells Fargo | Overweight |
Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
Jul-22-24 | Initiated | Needham | Buy |
Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-19-24 | Initiated | Robert W. Baird | Outperform |
Feb-06-24 | Initiated | UBS | Buy |
Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
Dec-13-23 | Initiated | Citigroup | Buy |
Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-05-23 | Initiated | Piper Sandler | Neutral |
Nov-01-22 | Initiated | Loop Capital | Buy |
Sep-07-22 | Resumed | Mizuho | Buy |
Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-10-21 | Initiated | Berenberg | Buy |
Jan-08-21 | Initiated | Jefferies | Buy |
Dec-16-20 | Initiated | Mizuho | Buy |
Sep-29-20 | Initiated | BofA Securities | Underperform |
Sep-10-20 | Initiated | Morgan Stanley | Overweight |
Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
Apr-14-20 | Initiated | Cowen | Outperform |
Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
Dec-16-19 | Reiterated | Guggenheim | Buy |
Oct-16-19 | Initiated | Guggenheim | Buy |
Sep-18-19 | Initiated | William Blair | Outperform |
May-28-19 | Initiated | SunTrust | Buy |
May-23-19 | Reiterated | H.C. Wainwright | Buy |
Apr-08-19 | Initiated | SVB Leerink | Outperform |
Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
Oct-03-16 | Resumed | Brean Capital | Buy |
Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Is Axsome Therapeutics Inc. stock gaining market shareDip Buying & Fast Gain Swing Trade Alerts - newser.com
Axsome Therapeutics Inc. stock trend forecast2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Axsome Therapeutics (AXSM) Stock Analysis: Unpacking A Potential 45% Upside In Biotech - DirectorsTalk Interviews
Axsome Therapeutics, Inc. $AXSM Shares Sold by Blair William & Co. IL - MarketBeat
Tools to assess Axsome Therapeutics Inc.’s risk profileMarket Movement Recap & AI Based Buy and Sell Signals - newser.com
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
IFP Advisors Inc Sells 4,096 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Q3 EPS Estimate for Axsome Therapeutics Reduced by Analyst - MarketBeat
Will Axsome Therapeutics Inc. (19X) stock deliver stable dividendsPortfolio Profit Report & Verified Swing Trading Watchlists - newser.com
Can trapped investors hope for a rebound in Axsome Therapeutics Inc.Gap Up & Verified Stock Trade Ideas - newser.com
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $1,590,330.30 in Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $1,518,062.16 in Stock - MarketBeat
Herriot Tabuteau Sells 19,220 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Axsome Therapeutics (AXSM): Exploring Valuation After Recent Share Price Stability - Yahoo Finance
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community - The Manila Times
Real time social sentiment graph for Axsome Therapeutics Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
1 in 5 U.S. adults affected — Axsome Recognizes Mental Illness Awareness Week and shares NAMI resources - Stock Titan
Axsome therapeutics CEO sells $5.4m in shares By Investing.com - Investing.com Canada
Axsome therapeutics CEO sells $5.4m in shares - Investing.com
Leerink Partnrs Issues Positive Forecast for AXSM Earnings - MarketBeat
Axsome Therapeutics Schedule Third Quarter 2025 Financial Results Announcement and Conference Call - Quiver Quantitative
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - The Manila Times
Knights of Columbus Asset Advisors LLC Grows Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Q3 2025 Results Nov 3: Axsome Therapeutics to Report Results and Host 8:00 AM ET Conference Call; Webcast - Stock Titan
Is Axsome Therapeutics Inc 19X a good long term investmentVolatility Adjusted Trading & Free Trading Psychology Sessions - earlytimes.in
Can Axsome Therapeutics Inc. stock withstand economic slowdownWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com
Will Axsome Therapeutics Inc. (19X) stock outperform global peersM&A Rumor & High Conviction Trade Alerts - newser.com
J. Safra Sarasin Holding AG Purchases 9,998 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Meet Herriot Tabuteau, The Haitian-Born Doctor Whose Brain Disorder Medications Turned Into A $6 Billion Empire - Black Enterprise
What is B. Riley's Estimate for AXSM Q3 Earnings? - MarketBeat
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation - Yahoo Finance
Migraine Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories - Barchart.com
Axsome Therapeutics (NASDAQ:AXSM) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
B. Riley Securities Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation - Nasdaq
AXSM: New 'Buy' Rating from B. Riley Securities with $179 PT | A - GuruFocus
How Axsome Therapeutics Inc. (19X) stock trades after rate cuts2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
B. Riley Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $179 - 富途牛牛
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN
H.C. Wainwright maintains Axsome stock Buy rating, $190 target - MSN
14 Best Biotech Stocks to Buy Right Now - Insider Monkey
Can Auvelity Drive Axsome's Growth Through the Rest of 2025? - The Globe and Mail
Obstructive Sleep Apnea Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma - Barchart.com
Obstructive Sleep Apnea Market Insights Highlight Expanding - openPR.com
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years - Mitrade
Axsome Sues Apotex to Block Copies of Symbravo Migraine Drug - Bloomberg Law News
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Option Exercise |
8.02 |
13,390 |
107,388 |
20,619 |
TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Option Exercise |
8.02 |
12,774 |
102,447 |
20,003 |
TABUTEAU HERRIOT | Chief Executive Officer |
Oct 06 '25 |
Sale |
120.17 |
19,220 |
2,309,667 |
7,229 |
TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Sale |
118.77 |
13,390 |
1,590,330 |
7,229 |
TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Sale |
118.84 |
12,774 |
1,518,062 |
7,229 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):